Established in 1988, Washington Biotechnology, Inc. is located in Baltimore, Maryland, U.S.A.
WBI Early-Stage Biotech/Pharma Services
WBI has a long and successful track record of providing in vivo services to emerging biotech and pharmaceutical companies in early stage development. In addition to our wide selection of disease models for cancer and inflammation, we can work with you to develop and validate custom models - with specialized expertise, economical pricing and rapid scheduling.
Washington Biotechnology, Inc. (WBI) is a leading In Vivo Services Contract Research Organization (CRO) for drug development.
For over 25 years we have provided our global biopharmaceutical clients with rapidly scheduled, accurate and cost-effective efficacy testing services.
Our clients drive innovation. We feel privileged to serve them in advancing treatments for human disease. In our role as CRO Partner, we are committed to the highest standards of science and project management.
We are continuously expanding and improving WBI's services to support our clients. This commitment sets us apart as "The In Vivo Services CRO Partner of Choice" for non-clinical in vivo efficacy testing.
Sign up for our newsletter to receive the most up-to-date information on our services.
WBI’s specialized In Vivo Efficacy Testing Services cover four major disease categories – Autoimmune and Inflammatory Diseases (including a separate category for Rheumatoid Arthritis), Cancer, Bacterial Infection and Pain. Complementary services include Pharmacokinetics (PK), Toxicity and Support Services.